8-K: Heron Therapeutics Reports Strong 2023 Oncology Sales, Reaffirms 2024 Guidance

Heron Therapeutics announced its fourth quarter and full-year 2023 financial results, highlighting strong oncology sales and reaffirming its 2024 financial guidance.

Summary

• Heron Therapeutics reported its financial results for the three and twelve months ended December 31, 2023.
• The company's oncology care franchise revenue reached $107.9 million for the full year 2023, exceeding its guidance.
• ZYNRELEF achieved a record quarterly revenue of $5.6 million in Q4 2023.
• The company ended 2023 with $80.4 million in cash and cash equivalents.
• A partnership with CrossLink Life Sciences was announced on January 7, 2024, to expand ZYNRELEF promotion.
• The FDA approved an expanded indication for ZYNRELEF on January 23, 2024.
• Gross margin improved to 71% for the quarter, up from 58% in the same period last year.
• The company reaffirmed its full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA.
• For 2024, product revenues are expected to be between $138.0 and $158.0 million.
• Adjusted operating expenses are projected to be between $108.0 and $116.0 million.
• Adjusted EBITDA is expected to be between $(22.0) and $3.0 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth and improved margins, but the company is still operating at a loss and has some risks. The reaffirmed guidance and product expansion are positive signals.

Positives

• The oncology care franchise exceeded full-year 2023 revenue guidance, reaching $107.9 million.
• ZYNRELEF achieved record quarterly sales of $5.6 million in Q4 2023.
• Gross margin improved to 71% for the quarter, a significant increase from 58% in the same period last year.
• The partnership with CrossLink Life Sciences will significantly expand the sales force for ZYNRELEF.
• The FDA approval for the expanded indication of ZYNRELEF opens up a larger market opportunity.
• The company reaffirmed its 2024 financial guidance, indicating confidence in future performance.
• The ZYNRELEF Vial Access Needle program is progressing as planned, with a launch expected in the second half of 2024.

Negatives

• The company reported a net loss of $10.7 million for the three months ended December 31, 2023, and a net loss of $110.6 million for the full year.
• The company cancelled the ZYNRELEF marketing authorization in the UK and EU, indicating a change in international strategy.
• The company's total operating expenses for the year were $172.6 million, which is higher than the $127 million in net product sales.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The company's ability to achieve profitability is not guaranteed.
• The company may need future equity financing to fund its operations.
• There is a risk of potential write-offs of additional inventory in the future.
• The company is involved in pending ANDA litigation, the outcome of which is uncertain.

Future Outlook

The company has reaffirmed its full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA, indicating a positive outlook for the coming year.

Management Comments

• Craig Collard, Chief Executive Officer of Heron, stated that the strategic decisions made over the past year have positioned the Company for long-term success and profitability.
• He also expressed pleasure in sharing the quarterly update and looks forward to building upon the achievements of the fourth quarter of 2023.

Industry Context

Heron Therapeutics operates in the competitive biotechnology and pharmaceutical industry, focusing on pain management and oncology supportive care. The company's performance is influenced by factors such as regulatory approvals, market adoption of its products, and competition from other pharmaceutical companies.

Comparison to Industry Standards

• Heron's gross margin of 71% in Q4 2023 is a strong result compared to the pharmaceutical industry average, which can vary widely but is often in the 60-70% range for branded products.
• The company's oncology franchise revenue of $107.9 million is a positive result, but it is important to compare this to other companies in the oncology space, such as companies like Exelixis or Clovis Oncology, which have similar market caps and product portfolios.
• The company's adjusted EBITDA guidance of $(22.0) to $3.0 million indicates that the company is still in a growth phase and not yet profitable, which is common for biotechnology companies in the commercialization stage.
• The expansion of ZYNRELEF's label to include approximately 13 million procedures annually is a significant market opportunity, but it is important to compare this to the market size of similar pain management products from companies like Pacira BioSciences.

Stakeholder Impact

• Shareholders may view the financial results and reaffirmed guidance positively.
• Employees may be encouraged by the company's growth and future prospects.
• Customers may benefit from the expanded availability and indications of the company's products.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's financial performance and future outlook.

Next Steps

• The company plans to submit a Prior Approval Supplement (PAS) for the ZYNRELEF Vial Access Needle (VAN) program in Q2 2024.
• The company anticipates launching the ZYNRELEF VAN program in the second half of 2024.
• The company expects to submit for approval the ZYNRELEF Prefilled Syringe (PFS) in 2026.

Key Dates

Keywords

Heron Therapeutics, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Oncology, Acute Care, Financial Results, FDA Approval, Pharmaceuticals, Biotechnology